Omniab, Inc. (OABI) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Omniab, Inc. (OABI) stock forecast summary
Our AI ranks Omniab, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Omniab, Inc. is a small-cap company with a market capitalization of $667M. It ranks number 7 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its D/E Ratio of 0.12x is the lowest of the 11 peers that report one.
For OABI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 47.0%, measured on 322 forecast dates between 2023-03-31 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 365 forecast dates between 2023-03-31 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, OABI included.
Follow OABI freeOABI price chart and AI forecast
How OABI ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Omniab, Inc. (OABI) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | OABI | Rank |
|---|---|---|
| Market Cap | $667M | 7/15 |
| P/B Ratio | 2.56x | 6/10 |
| EPS | $-0.47 | – |
| Book Value/Share | $1.79 | – |
| Revenue/Share | $0.26 | – |
| FCF/Share | $-0.12 | – |
Profitability & Margins
| Metric | OABI | Rank |
|---|---|---|
| ROE | -17.0% | 6/9 |
| ROA | -15.2% | 6/11 |
| ROIC | -17.5% | 10/11 |
| Operating Margin | -125.8% | 7/13 |
| Net Margin | -115.1% | 7/10 |
| EBT Margin | -118.9% | 8/13 |
| Tax Rate | 3.1% | – |
Financial Health
| Metric | OABI | Rank |
|---|---|---|
| Current Ratio | 4.80x | 3/16 |
| Quick Ratio | 4.72x | 2/6 |
| D/E Ratio | 0.12x | 11/11 |
| Financial Leverage | 1.12x | 10/10 |
| Working Capital | $52M | 5/15 |
Cash Flow
| Metric | OABI | Rank |
|---|---|---|
| Operating Cash Flow | -$18M | 13/15 |
| Free Cash Flow | -$18M | 5/7 |
| Capital Spending | -$470K | 2/7 |
| FCF/Sales | -47.2% | 5/8 |
| CapEx/Sales | 1.2% | 8/8 |
Operational Efficiency
| Metric | OABI | Rank |
|---|---|---|
| Asset Turnover | 0.13x | 8/8 |
| Receivables Turnover | 3.7x | 7/7 |
| Fixed Assets Turnover | 4.5x | 5/9 |
| Days Sales Outstanding | 98 days | 1/7 |
Income Statement
| Metric | OABI | Rank |
|---|---|---|
| Total Revenue | $38M | 5/8 |
| Operating Income | -$48M | 14/15 |
| Net Income | -$44M | 10/12 |
| R&D Expense | $44M | 3/7 |
Dividend & Shareholder Information
| Metric | OABI | Rank |
|---|---|---|
| Shares Outstanding | 145M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $66M | 22.7% of assets |
| Cash & Short-term Investments | $24M | 8.4% of assets |
| Accounts Receivable | $10M | 3.6% of assets |
| Inventory | $1M | 0.3% of assets |
| Total Liabilities | $30M | 10.3% of assets |
| Short-term Debt | $12M | 4.0% of assets |
OABI quarterly financials and insider trading
Omniab, Inc. (OABI) industry peers
Companies classified under the same SEC industry code as Omniab, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| OABI Omniab, Inc. | ▲ | $667M |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▶ | $22.20B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $27M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $2M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where OABI sits on the market map
Omniab, Inc. (OABI) stock news
Loading...
Omniab, Inc. (OABI) stock forecast FAQ
What is the Omniab, Inc. (OABI) stock forecast?
Our AI ranks Omniab, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Omniab, Inc. stock predictions?
For OABI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 47.0%, measured on 322 forecast dates between 2023-03-31 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 365 forecast dates between 2023-03-31 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Omniab, Inc. forecasts updated?
Omniab, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Omniab, Inc.'s industry peers?
16 issuers in our coverage, OABI included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.